198 related articles for article (PubMed ID: 21641409)
1. Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B.
Falcon BL; Pietras K; Chou J; Chen D; Sennino B; Hanahan D; McDonald DM
Am J Pathol; 2011 Jun; 178(6):2920-30. PubMed ID: 21641409
[TBL] [Abstract][Full Text] [Related]
2. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102.
Sennino B; Falcón BL; McCauley D; Le T; McCauley T; Kurz JC; Haskell A; Epstein DM; McDonald DM
Cancer Res; 2007 Aug; 67(15):7358-67. PubMed ID: 17671206
[TBL] [Abstract][Full Text] [Related]
3. Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis.
Hosaka K; Yang Y; Seki T; Nakamura M; Andersson P; Rouhi P; Yang X; Jensen L; Lim S; Feng N; Xue Y; Li X; Larsson O; Ohhashi T; Cao Y
Nat Commun; 2013; 4():2129. PubMed ID: 23831851
[TBL] [Abstract][Full Text] [Related]
4. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.
Sennino B; Kuhnert F; Tabruyn SP; Mancuso MR; Hu-Lowe DD; Kuo CJ; McDonald DM
Cancer Res; 2009 May; 69(10):4527-36. PubMed ID: 19401451
[TBL] [Abstract][Full Text] [Related]
5. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
Lu C; Shahzad MM; Moreno-Smith M; Lin YG; Jennings NB; Allen JK; Landen CN; Mangala LS; Armaiz-Pena GN; Schmandt R; Nick AM; Stone RL; Jaffe RB; Coleman RL; Sood AK
Cancer Biol Ther; 2010 Feb; 9(3):176-82. PubMed ID: 20009575
[TBL] [Abstract][Full Text] [Related]
6. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
Pietras K; Pahler J; Bergers G; Hanahan D
PLoS Med; 2008 Jan; 5(1):e19. PubMed ID: 18232728
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content.
McCarty MF; Somcio RJ; Stoeltzing O; Wey J; Fan F; Liu W; Bucana C; Ellis LM
J Clin Invest; 2007 Aug; 117(8):2114-22. PubMed ID: 17641778
[TBL] [Abstract][Full Text] [Related]
8. Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
Mancuso MR; Davis R; Norberg SM; O'Brien S; Sennino B; Nakahara T; Yao VJ; Inai T; Brooks P; Freimark B; Shalinsky DR; Hu-Lowe DD; McDonald DM
J Clin Invest; 2006 Oct; 116(10):2610-21. PubMed ID: 17016557
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells.
Yamaguchi SI; Ueki A; Sugihara E; Onishi N; Yaguchi T; Kawakami Y; Horiuchi K; Morioka H; Matsumoto M; Nakamura M; Muto A; Toyama Y; Saya H; Shimizu T
Cancer Sci; 2015 Jul; 106(7):875-82. PubMed ID: 25940371
[TBL] [Abstract][Full Text] [Related]
10. Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.
Sumida T; Kitadai Y; Shinagawa K; Tanaka M; Kodama M; Ohnishi M; Ohara E; Tanaka S; Yasui W; Chayama K
Int J Cancer; 2011 May; 128(9):2050-62. PubMed ID: 21387285
[TBL] [Abstract][Full Text] [Related]
11. Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model.
Jain RK; Lahdenranta J; Fukumura D
PLoS Med; 2008 Jan; 5(1):e24. PubMed ID: 18232729
[TBL] [Abstract][Full Text] [Related]
12. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
Hasumi Y; Kłosowska-Wardega A; Furuhashi M; Ostman A; Heldin CH; Hellberg C
Int J Cancer; 2007 Dec; 121(12):2606-14. PubMed ID: 17691110
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
[TBL] [Abstract][Full Text] [Related]
14. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.
Ruan J; Luo M; Wang C; Fan L; Yang SN; Cardenas M; Geng H; Leonard JP; Melnick A; Cerchietti L; Hajjar KA
Blood; 2013 Jun; 121(26):5192-202. PubMed ID: 23632889
[TBL] [Abstract][Full Text] [Related]
15. Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation.
Fuxe J; Tabruyn S; Colton K; Zaid H; Adams A; Baluk P; Lashnits E; Morisada T; Le T; O'Brien S; Epstein DM; Koh GY; McDonald DM
Am J Pathol; 2011 Jun; 178(6):2897-909. PubMed ID: 21550017
[TBL] [Abstract][Full Text] [Related]
16. PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer.
Liu J; Liao S; Huang Y; Samuel R; Shi T; Naxerova K; Huang P; Kamoun W; Jain RK; Fukumura D; Xu L
Clin Cancer Res; 2011 Jun; 17(11):3638-48. PubMed ID: 21459800
[TBL] [Abstract][Full Text] [Related]
17. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
[TBL] [Abstract][Full Text] [Related]
18. Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomas.
Lederle W; Linde N; Heusel J; Bzyl J; Woenne EC; Zwick S; Skobe M; Kiessling F; Fusenig NE; Mueller MM
Am J Pathol; 2010 Feb; 176(2):981-94. PubMed ID: 20042679
[TBL] [Abstract][Full Text] [Related]
19. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
20. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.
Lu C; Thaker PH; Lin YG; Spannuth W; Landen CN; Merritt WM; Jennings NB; Langley RR; Gershenson DM; Yancopoulos GD; Ellis LM; Jaffe RB; Coleman RL; Sood AK
Am J Obstet Gynecol; 2008 Apr; 198(4):477.e1-9; discussion 477.e9-10. PubMed ID: 18395047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
